Valuation: ImmuCell Corporation

Market Cap 9.93Cr 8.61Cr 8.07Cr 7.36Cr 14Cr 948.04Cr 14Cr 95Cr 37Cr 474.57Cr 37Cr 36Cr 1.58TCr P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 11Cr 9.42Cr 8.83Cr 8.06Cr 15Cr 1.04TCr 15Cr 104.02Cr 41Cr 519.41Cr 41Cr 40Cr 1.73TCr EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.43%
Yield 2024 *
-
Yield 2025 -
1 day+0.18%
1 week-0.18%
Current month-1.87%
1 month-0.72%
3 months+31.58%
6 months+66.67%
Current year+78.86%
1 week 10.47
Extreme 10.47
11.14
1 month 10.47
Extreme 10.47
12.1
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap.
27/01/26 Free

Chief Financial Officer

1,20,000 1.3266%
27/01/26 Free

Director

1,00,000 1.1055%
27/01/26 Free

Chief Executive Officer

1,09,500 1.2105%
Change 5-day change 1-year change 3-year change Capi.($)
+0.18%-0.18%+68.45%+119.12% 9.93Cr
-1.04%+1.48%+83.14%+124.83% 1,08800Cr
+0.49%+1.65%+49.76%+50.61% 63TCr
+0.79%+2.38%+23.93%+63.97% 44TCr
-0.88%-0.66%+45.09%+36.79% 36TCr
-0.37%-1.15%+26.89%+36.10% 29TCr
+0.05%-1.20%+2.31%+5.34% 25TCr
+0.39%+3.07%+44.22%+59.89% 23TCr
-0.42%+1.58%-8.48%-51.84% 20TCr
+1.63%+5.07%+14.44%+72.19% 17TCr
Average +0.20%+1.03%+34.97%+51.70% 36.49TCr
Weighted average by Cap. +0.00%+1.93%+45.89%+64.61%

Financials

2024 2025
Net sales 2.65Cr 2.3Cr 2.15Cr 1.96Cr 3.69Cr 252.85Cr 3.75Cr 25Cr 9.9Cr 126.57Cr 9.95Cr 9.73Cr 422.22Cr 2.76Cr 2.4Cr 2.25Cr 2.05Cr 3.85Cr 263.83Cr 3.92Cr 26Cr 10Cr 132.07Cr 10Cr 10Cr 440.57Cr
Net income -21.57L -18.69L -17.52L -15.98L -30.06L -21Cr -30.55L -2.06Cr -80.55L -10Cr -80.97L -79.21L -34Cr -10.4L -9L -8L -8L -14.5L -9.93Cr -14.73L -99.51L -38.85L -4.97Cr -39.05L -38.2L -17Cr
Net Debt 1.13Cr 98.31L 92.16L 84.03L 1.58Cr 108.24Cr 1.61Cr 11Cr 4.24Cr 54Cr 4.26Cr 4.17Cr 180.75Cr 93.88L 81.37L 76.28L 69.55L 1.31Cr 90Cr 1.33Cr 8.98Cr 3.51Cr 45Cr 3.52Cr 3.45Cr 149.61Cr
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
14/26/14 $11.00 +0.18% 39,283
12/26/12 $10.98 +0.27% 26,828
11/26/11 $10.95 -0.18% 14,489
10/26/10 $10.97 -0.27% 12,148
07/26/07 $11.00 -0.18% 9,705
  1. Stock Market
  2. Stocks
  3. ICCC Stock